Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Paradigm BiopharmaceuticalsASX:PAR 18 Equity-to-Asset is 0.26 as of Dec. 2025, which is 71% below its 10-year median of 0.91. GuruFocus rates ASX:PAR with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 1,415 Biotechnology companies, Paradigm Biopharmaceuticals ranks worse than 80.35% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Paradigm Biopharmaceuticals Equity-to-Asset Related Terms
Paradigm Biopharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PAR vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paradigm Biopharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Paradigm Biopharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Paradigm Biopharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paradigm Biopharmaceuticals (ASX:PAR) has a Equity-to-Asset of 0.26 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Paradigm Biopharmaceuticals and its competitors. This is 71% below median its historical median of 0.91. Over the past decade, Paradigm Biopharmaceuticals' Equity-to-Asset has ranged from 0.26 to 0.98. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #1137 out of 1415 companies in the Biotechnology industry, placing it in the top 80.4%.
Is Paradigm Biopharmaceuticals' Equity-to-Asset too high?
Paradigm Biopharmaceuticals' current Equity-to-Asset of 0.26 is 71% below median its 10-year median of 0.91. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 0.98. The Biotechnology industry median Equity-to-Asset is 0.68. Paradigm Biopharmaceuticals' value of 0.26 is 61.8% below this industry median. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #1137 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #1137 out of 1415 companies for Equity-to-Asset. This places Paradigm Biopharmaceuticals in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Paradigm Biopharmaceuticals' value of 0.26 is 61.8% below this benchmark. Historically, Paradigm Biopharmaceuticals' own Equity-to-Asset has ranged from 0.26 to 0.98 over the past decade. While the company's 10-year median is 0.91 vs. the industry median of 0.68, Paradigm Biopharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paradigm Biopharmaceuticals's current Equity-to-Asset of 0.26 is 61.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Paradigm Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paradigm Biopharmaceuticals's current Equity-to-Asset is 0.26, which is 71% below median its own 10-year median of 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Equity-to-Asset of 0.26. The current Equity-to-Asset is 0.26, which is 71% below median its 10-year median of 0.91 and 61.8% below the Biotechnology industry median of 0.68. Paradigm Biopharmaceuticals' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Equity-to-Asset is 0.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
18GF Score
Get the complete analysis for ASX:PAR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PAR has been successfully added to your 
